Trademark: 88299390
Word
VAYTESPO
Status
Registered
Status Code
700
Status Date
Tuesday, August 13, 2019
Serial Number
88299390
Registration Number
5834786
Registration Date
Tuesday, August 13, 2019
Mark Type
4
Filing Date
Wednesday, February 13, 2019
Published for Opposition
Tuesday, May 28, 2019

Trademark Owner History
Glaxo Group Limited - Original Registrant

Classifications
5 Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Trademark Events
Mar 6, 2019
New Application Office Supplied Data Entered
Feb 16, 2019
New Application Entered
Apr 23, 2019
Assigned To Examiner
Apr 23, 2019
Approved For Pub - Principal Register
May 8, 2019
Notification Of Notice Of Publication E-Mailed
May 28, 2019
Published For Opposition
May 28, 2019
Official Gazette Publication Confirmation E-Mailed
Aug 13, 2019
Registered-Principal Register
Nov 9, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Nov 9, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Nov 9, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Nov 9, 2022
Teas Change Of Correspondence Received
Nov 9, 2022
Teas Change Of Owner Address Received
Oct 9, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 9, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 9, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 9, 2023
Teas Change Of Correspondence Received
Oct 9, 2023
Teas Change Of Owner Address Received
Aug 13, 2024
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24